IP Library Granted Patent US 9,308,185
Granted Patent B2
US 9,308,185 · App. 13/189,113 · Granted Apr 12, 2016

Glyco-substituted dihydroxy-chlorins and β-functionalized chlorins for anti-microbial photodynamic therapy

Inventors: Daniel Aicher (Berlin, DE); Volker Albrecht (Nuthetal, DE); Burkhard Gitter (Jena, DE); Christian B. W. Stark (Leipzig, DE); Arno Wiehe (Berlin, DE)
Assignee: Biolitec Pharma Marketing LTD
A61K31/185A61K31/19A61K31/409A61K31/7056A61K41/0071A61K47/48092C07H15/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,308,185
App. No.
13/189,113
Granted
Apr 12, 2016
Kind
B2
Abstract

Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The conjugates are of the class of compounds of dihydroxychlorins or β-functionalized chlorins connected to carbohydrate moieties and having the general formula

Claims (37)

1. A carbohydrate and dihydroxychlorin conjugate compound comprising formula:

wherein B is independently selected from the group consisting of:

wherein each R is an independently selected substituent comprising one or more carbohydrate groups; and

wherein each R 2 is independently selected from the group consisting of alkyl or fluoroalkyl groups consisting of 1-15 carbon atoms, a phenyl ring, and a phenyl ring with one or more substituent X;

wherein said substituent X of the phenyl ring is in the ortho-, meta- or para-position of the phenyl ring;

wherein said substituent X is selected from the group consisting of OH, —COOH, —NH 2 , —CF 3 , —F, —COOY, —NHY, —OY, —NH—Z—COOH, and —CO—Z—NH 2 ;

wherein Y is selected from the group consisting of a polyethylene glycol residue containing a (CH 2 CH 2 O) n moiety with n=1-30 and a carbohydrate moiety; and

wherein Z is selected from the group of peptides and oligopeptides.

2. The compound according to claim 1 , based on the formula 3:

wherein each R comprises one or more carbohydrate groups;

wherein each R 1 is independently selected from the group consisting of alkyl or fluoroalkyl groups consisting of 1-15 carbon atoms, a phenyl ring, and a phenyl ring with one or more substituent X;

wherein said substituent X of the phenyl ring is in the ortho-, meta- or para-position of the phenyl ring;

wherein said substituent X is selected from the group consisting of OH, —COOH, —NH 2 , —F 3 , —F, —COOY, —NHY, —OY, —NH—Z—COOH, and —CO—Z—NH 2 ;

wherein Y is selected from the group consisting of a polyethylene glycol residue containing a (CH 2 CH 2 O) n moiety with n=1-30 and a carbohydrate moiety; and

wherein Z is selected from the group consisting of peptides and oligopeptides.

3. The compound according to claim 2 , wherein one or more substituent X is CF 3 .

4. The compound according to claim 1 , based on the formula 1:

wherein R 1 is a phenyl ring with a substituent X;

wherein said substituent X is in the ortho-, meta- or para-position;

wherein said substituent X is selected from the group consisting of a glucosyl, galactosyl, mannosyl, 2-acetamidoglucosyl, lactosyl, cellobiosyl, maltosyl and 3,4,6-trideoxy-3-(dimethylamino)-D-xylo-hexopyranosyl;

wherein each R 2 is independently selected from the group consisting of alkyl or fluoroalkyl groups consisting of 1-15 carbon atoms, and a phenyl ring substituted with one or more CF 3 -groups; and

wherein said CF 3 -groups are in the ortho-, meta- or para-position.

5. The compound according to claim 1 , based on the formulas 1 or 2:

wherein R 1 is a phenyl ring with one or more substituent X;

wherein said substituent X is in the ortho-, meta- or para- position;

wherein R 2 is a phenyl ring with a substituent X in the ortho-, meta- or para-position;

wherein said substituent X is selected from the group consisting of a glucosyl, galactosyl, mannosyl, 2-acetamidoglucosyl, lactosyl, cellobiosyl, maltosyl and 3,4,6-trideoxy-3-(dimethylamino)-D-xylo-hexopyranosyl;

wherein R 3 is selected from the group consisting of alkyl or fluoroalkyl groups consisting of 1-15 carbon atoms, and a phenyl ring substituted with one or more CF 3 -groups; and

wherein said CF 3 -groups are in the ortho-, meta- or para-position.

6. A composition comprising the compound according to claim 1 in an amount which is effective in destroying Gram-negative and Gram-positive microorganisms in the presence of a complex environment selected from the group consisting of saliva, blood, plasma and combinations thereof.

7. The compound according to claim 1 comprising formula:

8. The compound according to claim 1 comprising formula:

9. The compound according to claim 1 comprising formula:

10. The compound according to claim 1 , based on the formula 1:

wherein R 1 is a phenyl ring with a substituent X;

wherein said substituent X is either in the meta- or para-position;

wherein said substituent X is selected from the group of a glucosyl, galactosyl, mannosyl, 2-acetamidoglucosyl, lactosyl, cellobiosyl, maltosyl, and 3,4,6-trideoxy-3-(dimethylamino)-D-xylo-hexopyranosyl substituent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BIOLITEC PHARMA MARKETING LTD.; CERAMOPTEC GMBH
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 041187/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2013
From: CERAMOPTEC INDUSTRIES, INC.; CERAMOPTEC GMBH
To: CERAMOPTEC GMBH; BIOLITEC PHARMA MARKETING LTD.
Reel/Frame 030246/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2011
From: AICHER, DANIEL; STARK, CHRISTIAN B.W.; ALBRECHT, VOLKER; GITTER, BURKHARD; WIEHE, ARNO
To: CERAMOPTEC GMBH; CERAMOPTEC INDUSTRIES, INC.
Reel/Frame 026636/0364 →
Continuity (2)
Provisional Application 61366718 · Jul 22, 2010
Related Publication 20120263625A1 · Oct 18, 2012